Sheena Smith
Company: Vector BioPharma
Job title: Head of Program Management
Seminars:
Panel Discussion: War of the Payloads – Addressing the Advantages & Disadvantages of Transient VS Direct Integration 12:00 pm
• Discussing the use of non-stable integration with a DNA payload for greater safety and control • Discussing the challenges associated with stable integration, including lack of control in the context of proliferated cells • Re-thinking re-dosing strategies for enhanced efficacy • Evaluating the implications of removing lymphodepletion for in-vivo approaches, and associated effects on…Read more
day: Day 2
Precision Gene Delivery by SHREAD VLPs for Enhanced Safety and Efficacy In Vivo 1:00 pm
• Overview of Vector BioPharma’s proprietary SHielded Retargeted ADenovirus (SHREAD)-based virus-like particle (VLP) technology and key applications in cell therapy, immuno-oncology, genome editing and beyond • Interchangeable adapter technology for targeting VLP to specific tissues and cell types in vivo • Shielding and capsid engineering technologies for reducing immunogenicity and clearance of VLPsRead more
day: Day 1